As Founder, Chairman and CEO of Masimo, Joe Kiani runs one of the most admired medical technology companies in the world. He and his company are focused on solving the unsolvable problems plaguing patient monitoring. Under his leadership, Masimo has grown from a “garage start up” into a successful publicly traded company (NASDAQ: MASI) employing more than 4,500 people worldwide. Masimo’s technology has been shown to improve and save lives, including protecting the eyesight and lives of newborns. Over 100 million patients a year are monitored with Masimo’s measure-through-motion pulse oximetry technology.
With over 600 patents, Masimo’s innovations include Rainbow SET Pulse CO-Oximetry™—the first blood constituent monitoring platform to measure a dozen blood constituents noninvasively that previously could be measured only invasively, including hemoglobin. Kiani is named as an inventor on more than 190 U.S. patents, including measure-through-motion pulse oximetry.
Joe has earned over 50 awards for innovation and leadership, including the Hubert H. Humphrey Dawn of Life Award, Ernst & Young National Entrepreneur of the Year 2012 Life Sciences Award, and Society for Critical Care Medicine Technology Excellence Award.
Kiani is also the Chairman & CEO of Cercacor – a spinoff company from Masimo that is focused on developing noninvasive blood glucose and physiological monitoring technologies for diabetes patients and consumers.
In 2012, Kiani founded the non-profit Patient Safety Movement Foundation, with a commitment to eliminate preventable patient deaths in US hospitals and significantly reduce medical errors worldwide by the year 2020 (#0x2020). In February 2018, the hospitals and organizations that have joined the Patient Safety Movement reported 81,533 lives saved annually.